Preventing Alveolar Osteitis After Molar Extraction Using Chlorhexidine Rinse and Gel: A Meta-Analysis of Randomized Controlled Trials

Chia-Hui WANG1,7 • Shu-Hui YANG2,7 • Hsiu-Ju JEN3 • Jui-Chen TSAI4 • Hsi-Kuet LIN5 • El-Wui LOH6*

ABSTRACT

Background: Alveolar osteitis (AO) may occur after molar extraction. Chlorhexidine (CHX) rinse and CHX gel are widely used to prevent AO. Although previous meta-analyses support the effectiveness of both CHX rinse and CHX gel in preventing AO, important issues regarding these two formulations have not been addressed adequately in the literature.

Purpose: A systematic review and meta-analysis of randomized controlled trials was conducted to determine the effectiveness of CHX rinse and CHX gel in preventing AO.

Methods: PubMed, EMBASE, SCOPUS, and Cochrane databases were searched for randomized controlled trials published before June 2018. The risk ratio (RR) was used to estimate the pooled effect of AO incidence using a random-effect model.

Results: The RRs of AO in patients treated with 0.12% CHX rinse (RR = 0.54, 95% CI [0.41, 0.72]) and 0.2% CHX rinse (RR = 0.84, 95% CI [0.52, 1.35]) were significantly lower than in those treated with the control. Moreover, a significantly lower RR was identified in patients treated with 0.2% CHX gel (RR = 0.47, 95% CI [0.34, 0.64]) than in those treated with the control. When CHX products of different concentrations were grouped together, patients treated with CHX rinse showed an RR of AO of 0.61 (95% CI [0.48, 0.78]) and those treated with CHX gel showed an RR of AO of 0.44 (95% CI [0.43, 0.65]). On the other hand, a meta-analysis of three trials that compared CHX rinse and CHX gel directly showed a significantly lower RR of AO in patients treated with CHX rinse than in those treated with CHX gel (RR = 0.56, 95% CI [0.34, 0.96]).

Conclusions/Implications for Practice: The results support the effectiveness of both CHX rinse and gel in reducing the risk of AO after molar extraction. Each formulation provides unique benefits in terms of ease of application and cost. On the basis of the results of this study, the authors recommend that CHX gel be used immediately after molar extraction because of the convenience and cost-effectiveness of this treatment and that CHX rinse be used by the patient after discharge at home in combination with appropriate health education and case management.

Key Words: chlorhexidine, rinse, gel, alveolar osteitis.

Introduction

Alveolar osteitis (AO), the inflammation of the alveolar bone when an intra-alveolar blood clot disintegrates or fails to form, is one of the most common complications occurring after third molar (wisdom-tooth) extraction (Cardoso et al., 2010). AO usually manifests 2–5 days after surgery and is one of the main reasons for seeking postsurgical emergency appointments (Lee et al., 2015). Patients may experience fetid breath and persistent and radiating pain, which is not easily relieved by analgesics. The AO incidence after tooth extraction ranged from 3.2% to 6.14% in studies with large sample sizes (Abu Younis & Abu Hantash, 2011; Congiusta & Veitz-Keenan, 2013; Sigron et al., 2014) and even up to 35% in early studies (Erickson et al., 1960). Moreover, the risk of AO has been reported to be associated with the degree of difficulty involved in molar tooth extraction (Ogunlewe & Veitz-Keenan, 2013; Sigron et al., 2014).

1PhD, RN, Supervisor, Department of Nursing, Taipei Medical University Shuang Ho Hospital, and Assistant Professor, School of Nursing, College of Nursing, Taipei Medical University, Taiwan, ROC • 2BSN, RN, Department of Nursing, Taipei Medical University Shuang Ho Hospital, Tainan, ROC • 3BSN, RN, Head Nurse, Department of Nursing, Taipei Medical University Shuang Ho Hospital, and Adjunct Assistant Professor, School of Nursing, College of Nursing, Taipei Medical University, Taiwan, ROC • 4MSN, RN, Consultant, Department of Nursing, Taipei Medical University Shuang Ho Hospital, and Adjunct Assistant Professor, School of Nursing, College of Nursing, Taipei Medical University, Taiwan, ROC • 5DDS, Department of Dentistry, Taipei Medical University Shuang Ho Hospital, and Lecturer, School of Dentistry, College of Oral Medicine, Taipei Medical University, Tainan, ROC • 6PhD, Joint Appointment Medical Researcher, Center for Evidence-Based Health Care and Shared Decision Making Resource Center, Department of Medical Research, and Department of Dentistry, Taipei Medical University Shuang Ho Hospital; Researcher, Cochrane Taiwan, Taipei Medical University; and Assistant Professor, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan, ROC • 7contributed equally.

Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
and extraction, (Nusair & Younis, 2007).

A series of pharmacological agents, including antibacterial agents, antifibrinolytic agents, antiseptic agents, obtundent dressings, steroidal anti-inflammatory agents, clot-support agents, and growth-factor-rich plasma (Blum, 2002; Haraji et al., 2012), have each been examined for their potential in preventing AO. Chlorhexidine (CHX), an antiseptic agent developed in the 1940s, inhibits the growth of bacteria by increasing their cytoplasmic permeability and causing cell lysis. This agent is widely used for antibacterial purposes in hygiene control and surgery (Balagopal & Arjunkumar, 2013). CHX is available in the market in the form of different hygiene and treatment products such as chewing gum, toothpaste, spray, rinse, gel, and varnishes. Previous meta-analyses on both the gel and rinse formulations (Caso et al., 2005; Yengopal & Mickenautsch, 2012; Zhou et al., 2017) have suggested a prophylactic effect of CHX in terms of reducing the risk of AO after molar extraction. Although a recent systematic review and meta-analysis provided additional information on this issue, the focus of the review was on specific types of formulation (Dobson et al., 2018; Teshome, 2017) and more-recent publications were not covered (Rodriguez Sanchez et al., 2017).

A new meta-analysis of randomized controlled trials (RCTs) was performed in this study to evaluate the effectiveness of CHX rinse and CHX gel, the two most common types of CHX prophylactics, in preventing AO after molar extraction.

Methods

Literature Search
A search of the PubMed, EMBASE, SCOPUS, and Cochrane databases up to June 2018 was conducted to identify relevant trials. The following MeSH search headings were used: “alveolar osteitis,” “dry socket,” “alveolitis sicca dolorosa,” “fibrinolytic alveolitis,” “chlorhexidine,” “CHX,” “molar extraction,” “extraction,” “molar removal,” “molar surgery,” and “surgery.” These terms and their combinations were searched as text words. The “related articles” function in PubMed was used to broaden the scope of search. All of the abstracts, studies, and citations retrieved in this search were reviewed. In addition, other trials identified by manually searching the reference sections of the accessed articles and by contacting known experts in the field were reviewed. Furthermore, relevant unpublished trials registered on the ClinicalTrials.gov registry (http://clinicaltrials.gov/) and otherwise-unlisted articles searchable in Google Scholar were searched and reviewed as well. No language restrictions were applied.

Trial Selection
Trials that met the following criteria were included in the analysis: evaluating the efficacy of CHX rinse or gel in preventing AO in dental patients undergoing molar extraction or surgery, clearly stating the inclusion and exclusion criteria used to select patients for participation, and adequately describing the molar extraction or surgical procedures. Trials or data were excluded from analysis that examined additional components such as active gel-containing CHX and metronidazole versus placebo gel that would confound the contribution of CHX or that compared the efficacy of different CHX implication protocols of dosage, administration time, and treatment period. When duplicated articles with overlapping data sets were identified, the trial with the larger population was included.

Data Extraction and Quality Assessment
Two reviewers independently extracted the following information from each trial: first author, year of publication, trial population characteristics, trial design, inclusion and exclusion criteria, matching criteria, definition of molar tooth extraction, and incidence of AO. The retrieved studies were assessed for eligibility by the two reviewers according to the specified inclusion criteria. The individually recorded decisions of the two reviewers were compared, and any disagreements were resolved by a third reviewer.

The quality of the retrieved trials was assessed using the revised Cochrane risk-of-bias tool for randomized trials Version 2 recommended by the Cochrane Collaboration (Higgins et al., 2019). Two reviewers conducted the assessment, and any disagreement was resolved by a third reviewer. Five domains were assessed, including bias arising from the randomization process, bias due to deviations from intended interventions (effect adhering to intervention), bias due to missing outcome data, bias in measuring outcomes, and bias in selecting the reported results.

Data Synthesis and Analysis
The statistical package Review Manager, Version 5.3 (Cochrane Collaboration, Oxford, England) was used to analyze the data. The meta-analysis was performed according to the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (Moher et al., 2009). When necessary, standard deviations were estimated using the provided confidence interval (CI) limits, standard error, or range values.

Data were pooled only for trials that reported sufficiently similar clinical and methodological variables. A pooled estimate of risk ratio (RR) was computed using the DerSimonian and Laird random-effect model (DerSimonian & Laird, 1986). Heterogeneity among the trials was assessed using the I² test and a null hypothesis test, in which \( p < .1 \) was considered to represent significant outcome heterogeneity. Because the included trials used CHX in rinse or gel formulations at different CHX concentrations, subgroup analyses were conducted according to their packing materials (rinse or gel) and CHX concentrations to examine differences attributable to differences in composition.
Results

Trial Characteristics

The procedures used in sampling are summarized in Figure 1. The initial search yielded 202 records, of which 145 records were excluded because of duplication. After a brief reading of the title and abstract, a further 99 records, including 14 short publications, 45 reviews (narrative review and systematic review and meta-analysis), three non-RCTs, one cohort study, and 36 dentistry articles, were excluded because of lack of relevance to the scope of this review. The full contents of the remaining 46 records were retrieved for evaluation. Subsequently, 23 records were excluded, including four RCTs that tested CHX mixed with other materials; one RCT that was not restricted to molar extraction; 16 RCTs that tested CHX dosage, administration time, or treatment period; and one RCT that used a duplicate sample. Of the remaining 23 trials, 20 were identified from the academic databases and three (Ahmedi et al., 2014; Shaban et al., 2014; Younus et al., 2014) were identified through Google Scholar. The data from these 23 trials were used in analysis, and their characteristics are presented in Table 1. The included studies were published between 1991 and 2017 and had sample sizes of 30–271 patients. Seven of the trials examined the effectiveness of CHX rinse, 13 examined the effectiveness of CHX gel, and three examined the comparative effectiveness of CHX rinse and CHX gel. In terms of controls, a subject–subject case–control design was used in 18 of the trials, and a split-mouth case–control design was used in five of the trials. All of the included trials restricted their subjects to single third molar or bilateral third molar extractions with the

Figure 1
Sampling Procedures

![Diagram of sampling procedures]

- **Database Search (n = 202)**
  - Embase (n = 133)
  - PubMed (n = 64)
  - Reference section & Google Scholar (n = 5)

- **Records after removing redundancy (n = 145)**

- **Screening on title and abstract**

- **Full-text assessment for eligibility (n = 46)**

- **Trials included for systematic review & synthesis (n = 23)**

### Nonrelevance (n = 99)
1. Note, commentary, conference abstract, and reply (n = 14)
2. Narrative review and systematic review & meta-analysis (n = 45)
3. Non-RCTs (n = 3)
4. Cohort study (n = 1)
5. Unrelated topics (n = 36)

### RCTs excluded (n = 23)
1. CHX mixed with other materials (n = 4)
2. CHX not restricted to molar extraction (n = 1)
3. CHX dosage, administration time, or treatment period (n = 16)
4. Non-CHX materials (n = 1)
5. Duplicated sample (n = 1)

Note. RCT = randomized controlled trial; CHX = chlorhexidine.
## Table 1
Characteristics of the Selected Randomized Controlled Trials

| Trial/Author (Year) | Inclusion Criteria | No. of Patients (% Male) | Mean Age or Mean Age ± SD | Treatment |
|---------------------|--------------------|--------------------------|---------------------------|-----------|
| **Rinse vs. control** |                     |                          |                           |           |
| 1. Berwick & Lessin (1990) | Bilateral max. third molars | I: 20 (NA) C: 20 (NA) | 21.4 | I: 0.12% CHX rinse for 1 min before surgery C: NSR after surgery |
| 2. Channar et al. (2013) | Mand. third molar | I: 73 (NA) C: 72 (NA) | 30.4 ± 5.2 | I: 0.2% CHX rinse (15 ml for 30 s), twice daily for 7 days after surgery C: NSR |
| 3. Delibasi et al. (2002) | Mand. third molar | I: 62 (48.0) C: 59 (42.4) | 24.1 | I: 0.2% CHX rinse (15 ml for 30 s) before surgery and twice daily for 7 days after surgery C: NSR before surgery and twice daily for 7 days after surgery |
| 4. Hermesch et al. (1998) | ≥ 1 Mand. third molar | I: 136 (37.5) C: 135 (37.0) | 22.2 | I: 0.12% CHX rinse (15 ml for 30 s), twice daily for 7 days before and 7 days after surgery C: 11.6% alcohol (15 ml for 30 s), twice daily for 7 days before and 7 days after surgery |
| 5. Larsen (1991) | Bilateral mand. third molars | I: 73 (43.8) C: 67 (44.8) | NA | I: 0.12% CHX rinse (15 ml for 30 s), twice daily for 7 days before and 7 days after surgery C: Identical solution without CHX (15 ml for 30 s), twice daily for 7 days before and 7 days after surgery |
| 6. Osunde et al. (2017) | Mand. third molars | I: 50 (48) C: 50 (44) | 26.4 ± 5.1 | I: Gargle with 0.12% CHX gluconate rinse twice daily C: Gargle with warm NSR twice daily |
| 7. Ragno & Szkutnik (1991) | Mand. third molars | I: 80 C: 80 | NA | I: 0.12% CHX rinse. Rinse with 15 ml before suture and then the day after surgery (15 ml for 30 s), twice daily for 7 days C: Placebo. Rinse with 15-ml placebo solution before suture and then the day after surgery (15 ml for 30 s), twice daily for 7 days |
| **Gel vs. control** |                     |                          |                           |           |
| 8. Ahmedi et al. (2014) | Bilateral mand. third molars | I: 25 C: 25 | NA | I: 2-ml 1% CHX digluconate gel into alveolus before suture C: NSR of alveolus before suture |
| 9. Babar et al. (2012) | Mand. third molar | I: 50 (78) C: 50 (54) | 29 ± 6 | I: 0.2% CHX gel into alveolus C: No treatment |
| 10. Freudenthal et al. (2015) | Mand. third molars | I: 48 (51) C: 47 (44) | 33 | I: 10-ml Cervitec gel (0.2% CHX and 0.2 sodium fluoride) into alveolus before suture C: 10-ml placebo gel (0.2% sodium fluoride) into alveolus before suture |
| 11. Haraji et al. (2013) | Bilateral mand. third molars | I: 80 (48.8) C: 80 (48.8) | 21.6 ± 2.5 | I: 0.2% CHX gel into alveolus before suture C: Dry dressing into alveolus before suture |
| 12. Haraji & Rakhshan (2014) | Bilateral mand. third molars | I: 45 (53.3) C: 45 (53.3) | 22.1 ± 2.7 | I: 0.2% CHX gel into alveolus before suture C: Dry dressing into alveolus before suture |
| 13. Jesudasan et al. (2015) | Mand. third molars | I: 90 C: 90 | 28 ± 6 | I: 0.2% CHX gel into alveolus before suture C: No treatment before suture |

(continues)
exceptions of Khan et al. (2015) and Abu-Mostafa et al. (2015), which allowed the extraction of any molar tooth.

The methodological quality of the eligible trials is presented in Table 2. All of the included trials reflected low risk of bias because of either deviations from intended interventions or missing outcome data. The low risk is likely attributable to the high level of motivation that the participants had in reducing postoperative pain and in returning for follow-up examinations. However, all of the included trials reflected some level of concern with regard to bias in reporting results, as none mentioned the registration of their protocols. Most of the included trials had either a low risk or some concerns for bias related to the randomization process, although one trial that compared CHX gel and the control and three trials that compared CHX rinse and CHX gel were found to reflect a high risk of bias in the domain. The participants in those trials that compared CHX rinse and CHX gel would know their allocation sequences even if the allocation was random. Furthermore, the one trial that compared CHX gel and the control had a high risk of bias in randomization process because no treatment was provided to the controlled subjects. Finally, there was a mixture of classes of bias in terms of outcome measurement, with 13 deemed at a low risk, six deemed as having some concerns, and four deemed at a high risk.

### Incidence of Alveolar Osteitis

**Chlorhexidine rinse versus control**

Five of the included trials compared the incidence of AO between a 0.12% CHX rinse group and a control group...
(Berwick & Lessin, 1990; Hermesch et al., 1998; Larsen, 1991; Osunde et al., 2017; Ragno & Szkutnik, 1991), and two trials compared the incidence of AO between a 0.2% CHX rinse group and a control group (Channar et al., 2013, Delilbasi et al., 2002). These trials were analyzed in two subgroups, with the results presented in Figure 2. The RR of AO in patients treated with 0.12% CHX rinse was significantly lower than that in patients treated with the control (RR = 0.54, 95% CI [0.41, 0.72]), with no heterogeneity across trials ($I^2 = 0\%$, $p = .73$). Furthermore, the RR of AO in patients treated with 0.2% CHX rinse was significantly lower than that in patients treated with the control (RR = 0.84, 95% CI [0.52, 1.35]), with no significant heterogeneity across trials ($I^2 = 56.4\%$, $p = .13$) and significant heterogeneity across trials ($I^2 = 0\%$, $p = .62$).

### Table 2

**Assessment of the Methodological Quality of Selected Trials Using the Revised Cochrane Risk-of-Bias Tool for Randomized Trials (Version 2)**

| Trial                                | Randomisation | Deviation From Intended Interventions | Missing Outcome | Measurement of Outcome | Reporting | Overall |
|--------------------------------------|---------------|--------------------------------------|-----------------|------------------------|-----------|---------|
| CHX Rinse vs. control                |               |                                      |                 |                        |           |         |
| 1. Berwick & Lessin (1990)           | LR            | LR                                   | LR              | LR                     | SC        | SC      |
| 2. Channar et al. (2013)              | SC            | LR                                   | LR              | LR                     | SC        | SC      |
| 3. Delilbasi et al. (2002)            | LR            | LR                                   | LR              | LR                     | SC        | SC      |
| 4. Hermesch et al. (1998)            | LR            | LR                                   | LR              | LR                     | SC        | SC      |
| 5. Larsen (1991)                      | LR            | LR                                   | LR              | LR                     | SC        | SC      |
| 6. Osunde et al. (2017)               | LR            | LR                                   | LR              | LR                     | SC        | SC      |
| 7. Ragno & Szkutnik (1991)            | LR            | LR                                   | LR              | LR                     | SC        | SC      |
| CHX Gel vs. control                  |               |                                      |                 |                        |           |         |
| 8. Ahmedi et al. (2014)               | LR            | LR                                   | LR              | HR                     | SC        | HR      |
| 9. Babar et al. (2012)                | SC            | LR                                   | LR              | HR                     | SC        | HR      |
| 10. Freudenthal et al. (2015)         | LR            | LR                                   | LR              | LR                     | SC        | SC      |
| 11. Haraji et al. (2013)              | SC            | LR                                   | LR              | LR                     | SC        | SC      |
| 12. Haraji & Rakhshan (2014)          | SC            | LR                                   | LR              | LR                     | SC        | SC      |
| 13. Jesudasan et al. (2015)           | SC            | LR                                   | LR              | LR                     | SC        | SC      |
| 14. Khan et al. (2015)                | SC            | LR                                   | LR              | SC                     | SC        | SC      |
| 15. Requena-Calla & Funes-Rumiche (2016) | SC         | LR                                   | LR              | HR                     | SC        | HR      |
| 16. Rubio-Palau et al. (2015)         | SC            | LR                                   | LR              | SC                     | SC        | SC      |
| 17. Shaban et al. (2014)              | HR            | LR                                   | LR              | LR                     | SC        | HR      |
| 18. Torres-Lagares, Infante-Cossio, et al. (2006) | SC         | LR                                   | LR              | SC                     | SC        | SC      |
| 19. Torres-Lagares, Gutierrez-Perez, et al. (2006) | LR         | LR                                   | LR              | LR                     | SC        | SC      |
| 20. Torres-Lagares et al. (2010)      | SC            | LR                                   | LR              | LR                     | SC        | SC      |
| CHX Rinse vs. gel                    |               |                                      |                 |                        |           |         |
| 21. Abu-Mostafa et al. (2015)         | HR            | LR                                   | LR              | SC                     | SC        | HR      |
| 22. Hita-Iglesias et al. (2008)       | HR            | LR                                   | LR              | HR                     | SC        | HR      |
| 23. Younus et al. (2014)              | HR            | LR                                   | LR              | SC                     | SC        | HR      |

**Note.** LR = low risk; SC = some concerns; HR = high risk.
was significant (RR = 0.45, 95% CI [0.33, 0.62]), with insignificant heterogeneity ($I^2 = 15\%$, $p = .29$) and differences between subgroups ($I^2 = 0\%$, $p = .52$) across all trials.

**Subgroup difference**

To examine whether effectiveness in reducing the risk of AO differed between CHX rinse and CHX gel, all of the CHX rinse trials were analyzed in one group, whereas all of the CHX gel trials were analyzed in a separate group. The results are summarized in Figure 4. No significant subgroup difference was observed ($I^2 = 53.7\%$, $p = .14$).

**Chlorhexidine rinse versus chlorhexidine gel**

Three trials compared the incidence of AO in the CHX rinse and CHX gel groups (Abu-Mostafa et al., 2015; Hita-Iglesias et al., 2008; Younus et al., 2014). The results of the meta-analysis showed a significantly lower incidence of AO in patients treated with CHX rinse than those treated with CHX gel (RR = 0.61, 95% CI [0.39, 0.95]; table not shown because of space limitations and may be obtained by contacting the corresponding author). No heterogeneity was observed across trials ($I^2 = 41\%$, $p = .18$).

**Discussion**

In this study, using either CHX rinse or CHX gel after molar extraction was found to reduce the risk of AO. The subgroup analysis showed no difference between the CHX rinse trials and CHX gel trials in terms of AO risk. On the other hand, a meta-analysis of the three trials that compared CHX rinse and CHX gel suggested that CHX rinse is better than CHX gel in preventing AO.

It seems confusing at the first glance when looking at the insignificant difference between subgroups of all CHX rinse trials and all CHX gel trials and the significant effects resulting from the comparison of CHX rinse and CHX gel. This strongly suggests the presence of a methodology problem. The RR of a trial is affected by many factors, one of which is the treatment received by the control group. For example, saline control likely affords a certain level of AO prevention, whereas the option of no treatment probably has no AO prevention effect. Phenomena such as this affect the results to some extent and, unfortunately, are unable to be statistically adjusted for in the current study design. On the other hand, the number of trials used in the meta-analysis comparing CHX rinse and CHX gel was relatively small. Nevertheless, CHX gel appears to offer a few practical advantages over CHX rinse. First, only one application of CHX gel is required after molar extraction, whereas several days of CHX rinse are required. This implies that no further prescription is required for patients treated with CHX gel. However, an at-home CHX rinse must be prescribed for patients following the CHX rinse protocol along with additional health education to ensure compliance. In terms of cost, the market price of a 200-ml bottle of CHX rinse is approximately US$3. CHX rinse may be used by a single patient only because of hygienic concerns. By comparison, the market price of a 50-ml tube of CHX gel is approximately US$23.3.
However, the gel can be used by 25 patients in a clinic (presuming 2 ml/patient) at a cost of less than US$1 per patient (price information obtained from the National Health Insurance, Taiwan). Certainly, the way that CHX products are applied affects their actual efficacies. For example, a recent RCT showed that irrigation of the molar surgical site with CHX had a better AO prevention effect than simply rinsing the mouth with CHX (Cho et al., 2018). Moreover, reducing the risk of AO reduces the need for return clinic visits because of extraction complications. In addition to benefits of treatment, side effects should be considered when evaluating treatment efficacy. Staining and bitter taste are two common side effects of CHX (Flötra et al., 1971; Tilliss, 1999) that have been at least partially addressed in newer CHX products (Raszewski et al., 2019). Practitioners may provide or recommend choices of CHX products to maximize their usage while minimizing their side effects and maintaining the targeted prophylactic effects. Another issue that should be noted is the potential that patients may exhibit an allergic reaction to CHX. A patch test involving 7,610 general dermatology patients using CHX digluconate (0.5% aqueous) revealed a 0.47% positive reaction in the sample (Liippo et al., 2011). Although the actual situation of CHX allergy in dentistry remains to be investigated (Pemberton & Gibson, 2012), precautions should be taken, especially among patients with a history of CHX contact allergy.

The trials included in our analysis showed considerable heterogeneity because of various backgrounds and clinical factors. Although most of the trials reported information on age and gender, which are known factors attributable to AO, some trials did not provide clear information on these basic variables. Whether all of the included trials examined young adults as revealed by most of the reported information could not be confirmed. Moreover, although we restricted the trials to molar extractions, we did not restrict the diagnostic criteria and molar extraction methods or narrow the target to a specific tooth (e.g., the third molar), nor did the standard used to diagnose AO. In addition, the experimental (i.e., methods of CHX rinse or CHX gel use) and control methods differed in the included trials. Other factors such as working experience and analgesics use that may affect the outcomes of surgery varied across the trials.
Our meta-analysis had some limitations. First, although molar extraction is a routine dental procedure worldwide, the number of RCTs related to AO and CHX rinse or gel is relatively low. Second, the included trials were conducted in a limited number of countries. Because overall oral health may vary across populations, the AO risk revealed in our results may differ slightly from the real-world situation in clinics.

Implication for Practice
Both CHX rinse and gel treatments may be used after molar extraction to reduce the risk of AO. Although this measure improves health outcomes and dental health service quality, it only increases the treatment costs slightly. The findings of this review support the use of CHX rinse or gel in molar extraction surgery, whether covered by national insurance or self-pay. For convenience and affordability, CHX gel applied immediately after molar extraction by the dentist is recommended. The at-home CHX rinse is recommended as long as the dental clinic is able to provide appropriate health education and case management support.

Acknowledgments
This study was funded by the Taipei Medical University (grant number: TMU107-AE1-B05) and Taipei Medical University Shuang Ho Hospital (grant number: 106HCP-17).

Author Contributions
Study conception and design: CHW, SHY, EWL
Data collection: HJJ, JCT, HKL
Data analysis and interpretation: All authors
Drafting of the article: CHW, SHY
Critical revision of the article: EWL
References

*References marked with an asterisk indicate studies included in the meta-analysis.

Abu Younis, M. H., & Abu Hantash, R. O. (2011). Dry socket: Frequency, clinical picture, and risk factors in a Palestinian dental teaching center. *Open Dentistry Journal*, 5, 7–12. https://doi.org/10.2174/1874210601105010007

*Abu-Mostafa, N. A., Alqahtani, A., Abu-Hasna, M., Alhokail, A., & Aladsani, A. (2015). A randomized clinical trial compared the effect of intra-alveolar 0.2% chlorhexidine bio-adhesive gel versus 0.12% chlorhexidine rinse in reducing alveolar osteitis following molar teeth extractions. *Medicina Oral Patología Oral y Cirugía Bucale* (2011), e82-e87. https://doi.org/10.4317/medoral.19932

*Ahmedi, J., Ahmedi, E., Agani, Z., Hamiti, V., Reçica, B., & Tmava-Dragusha, A. (2014). The efficacy of 1% chlorhexidine gel on the reduction of dry socket occurrence following surgical third molar extraction-pilot study. *Open Journal of Stomatology*, 4(3), 152–160. https://doi.org/10.4236/ojst.2014.43023

*Babar, A., Ibrahim, M. W., Baig, N. J., Shah, I., & Amin, E. (2012). Efficacy of intra-alveolar chlorhexidine gel in reducing frequency of alveolar osteitis in mandibular third molar surgery. *Journal of the College of Physicians and Surgeons-Pakistan*, 22(2), 91–94.

Balagopal, S., & Arjunkumar, R. (2013). Chlorhexidine: The gold standard antiplaque agent. *Journal of Pharmaceutical Sciences and Research*, 5(12), 270–274.

*Berwick, J. E., & Lessin, M. E. (1990). Effects of a chlorhexidine gluconate oral rinse on the incidence of alveolar osteitis in mandibular third molar surgery. *Journal of Oral and Maxillofacial Surgery*, 48(5), 444–448. https://doi.org/10.1016/0228-2391(90)90227-S

Blum, I. R. (2002). Contemporary views on dry socket (alveolar osteitis): A clinical appraisal of standardization, aetiopathogenesis and management: A critical review. *International Journal of Oral and Maxillofacial Surgery*, 31(3), 309–317. https://doi.org/10.1054/ijom.2002.0263

Cardoso, C. L., Rodrigues, M. T. V., Ferreira, O. Jr., Garlet, G. P., & de Carvalho, P. S. (2010). Clinical concepts of dry socket. *Journal of Oral and Maxillofacial Surgery*, 68(8), 1922–1932. https://doi.org/10.1016/j.joms.2009.09.085

Casio, A., Hung, L. K., & Beirne, O. R. (2005). Prevention of alveolar osteitis with chlorhexidine: A meta-analytic review. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics*, 99(2), 155–159. https://doi.org/10.1016/j.tripleo.2004.05.009

*Channar, K. A., Dall, A. Q., Memon, A. B., & Lal, B. (2013). Prevention of alveolar osteitis in surgical removal of lower third molar. *Pakistan Oral & Dental Journal*, 32(2), 244–248.

Cho, H., David, M. C., Lynham, A. J., & Hsu, E. (2018). Effectiveness of irrigation with chlorhexidine after removal of mandibular third molars: A randomised controlled trial. *British Journal of Oral and Maxillofacial Surgery*, 56(1), 54–59. https://doi.org/10.1016/j.bjoms.2017.11.010

Congiusta, M. A., & Veitz-Keenan, A. (2013). Study confirms certain risk factors for development of alveolar osteitis. *Evidence-Based Dentistry*, 14(3), Article 86. https://doi.org/10.1038/sj.ebd.6400954

*Delibasi, C., Saracoglu, U., & Keskin, A. (2002). Effects of 0.2% chlorhexidine gluconate and amoxicillin plus clavulanic acid on the prevention of alveolar osteitis following mandibular third molar extractions. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics*, 94(3), 301–304.

DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. *Controlled Clinical Trials*, 7(3), 177–188. https://doi.org/10.1016/0197-2456(86)90046-2

Dobson, M., Pillon, L., Kwon, O., & Innes, N. (2018). Chlorhexidine gel to prevent alveolar osteitis following mandibular third molar extractions. *Evidence-Based Dentistry*, 19(1), 16–17. https://doi.org/10.1038/sj.ebd.6401288

Erickson, R. I., Waite, D. E., & Wilkison, R. H. (1960). A study of dry sockets. *Oral Surgery, Oral Medicine, and Oral Pathology*, 13(9), 1046–1050. https://doi.org/10.1016/0030-4220(60)90316-9

Flötta, L., Gjermo, P., Rölla, G., & Waerhaug, J. (1971). Side effects of chlorhexidine mouth washes. *Scandinavian Journal of Dental Research*, 79(2), 119–125. https://doi.org/10.1111/j.1600-0722.1971.tb00201.x

*Freudenthal, N., Sternudd, M., Jansson, L., & Wannfors, K. (2015). A double-blind randomized study evaluating the effect of intra-alveolar chlorhexidine gel on alveolar osteitis after removal of mandibular third molars. *Journal of Oral and Maxillofacial Surgery*, 73(4), 600–605. https://doi.org/10.1016/j.joms.2014.08.035

Haraji, A., Lassemi, E., Motamedi, M. H. K., Alavi, M., & Adibnejad, S. (2012). Effect of plasma rich in growth factors on alveolar osteitis. *National Journal of Maxillofacial Surgery*, 3(1), 38–41. https://doi.org/10.4103/0975-5950.102150

*Haraji, A., & Rakshan, V. (2014). Single-dose intra-alveolar chlorhexidine gel application, easier surgeries, and younger ages are associated with reduced dry socket risk. *Journal of Oral and Maxillofacial Surgery*, 72(2), 259–265. https://doi.org/10.1016/j.joms.2013.09.023

*Haraji, A., Rakshan, V., Khamverdi, N., & Alishahi, H. K. (2013). Effects of intra-alveolar placement of 0.2% chlorhexidine bioadhesive gel on dry socket incidence and postsurgical pain: A double-blind split-mouth randomized controlled clinical trial. *Journal of Oral and Facial Pain and Headache*, 27(3), 256–262. https://doi.org/10.11607/jop.1142

*Hermesch, C. B., Hilton, T. J., Biesbrock, A. R., Baker, R. A., Cain-Hamlin, J., McClanahan, S. F., & Gerlach, R. W. (1998). Perioperative use of 0.12% chlorhexidine gluconate for the prevention of alveolar osteitis: Efficacy and risk factor analysis. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics*, 85(4), 381–387. https://doi.org/10.1016/S0179-2104(98)90061-0

Higgins, J. P. T., Savovic, J., Page, M. J., & Sterne, J. A. C.; on behalf of the ROB2 Development Group. (2019). *Revised Cochrane risk-of-bias tool for randomized trials (ROB 2)*. https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2
*Hita-Iglesias, P., Torres-Lagares, D., Flores-Ruiz, R., Magallanes-Abad, N., Basallote-Gonzalez, M., & Gutierrez-Perez, J. L. (2008). Effectiveness of chlorhexidine gel versus chlorhexidine rinse in reducing alveolar osteitis in mandibular third molar surgery. Journal of Oral and Maxillofacial Surgery, 66(3), 441–445. https://doi.org/10.1016/j.joms.2007.06.641

*Jesudasan, J. S., Wahab, P. U., & Sekhar, M. R. (2015). Effective-Chlorhexidine and Alveolar Osteitis

*Ragno, J. R. Jr., & Szkutnik, A. J. (1991). Evaluation of 0.12% Pemberton, M. N., & Gibson, J. (2012). Chlorhexidine and hyper-

*Khan, M. A., Bashir, S., Khan, F. R., Umer, F., Haider, S. M., & Hasan, T. (2015). Clinical efficacy of single dose chlorhexidine gel application in molar extractions—A randomized clinical trial. Journal of the Pakistan Dental Association, 24(4), 175–181.

*Larsen, P. E. (1991). The effect of a chlorhexidine rinse on the incidence of alveolar osteitis following the surgical removal of impacted mandibular third molars. Journal of Oral and Maxillofacial Surgery, 49(9), 932–937. https://doi.org/10.1016/0278-2391(91)90055-Q

Lee, C. T., Zhang, S., Leung, Y. Y., Li, S. K., Tsang, C. C., & Chu, C. H. (2015). Patients’ satisfaction and prevalence of complications on surgical extraction of third molar. Patient Preference and Adherence, 9, 257–263. https://doi.org/10.2147/PPA.S76236

Liippo, J., Kousa, P., & Lamminen, A. K. (2011). The relevance of chlorhexidine contact allergy. Contact Dermatitis, 64(4), 229–234. https://doi.org/10.1111/j.1600-0536.2010.01851.x

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G., for the PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ, 339, Article b2535. https://doi.org/10.1136/bmj.b2535

Nusair, Y. M., & Younis, M. H. A. (2007). Prevalence, clinical picture, and risk factors of dry socket in a Jordanian dental teaching center. The Journal of Contemporary Dental Practice, 8(3), 53–63.

Ogunlewe, M. O., Adeyemo, W. L., Ladeinde, A. L., & Taiwo, O. A. (2007). Incidence and pattern of presentation of dry socket following non-surgical tooth extraction. Nigerian Quarterly Journal of Hospital Medicine, 17(4), 126–130.

*Osende, O. D., Anyanwum, C. E., & Bassey, G. O. (2017). Prevention of alveolar osteitis after third molar surgery: Comparative study of the effect of warm saline and chlorhexidine mouth rinses. Nigerian Journal of Clinical Practice, 20(4), 470–473. https://doi.org/10.4103/1199-3077.180064

Pemberton, M. N., & Gibson, J. (2012). Chlorhexidine and hypersensitivity reactions in dentistry. British Dental Journal, 213(11), 547–550. https://doi.org/10.1038/sj.bdj.2012.1086

*Ragno, J. R. Jr., & Szukutnik, A. J. (1991). Evaluation of 0.12% chlorhexidine rinse on the prevention of alveolar osteitis. Oral Surgery, Oral Medicine, and Oral Pathology, 72(5), 524–526. https://doi.org/10.1016/0030-4220(91)90487-W

Raszewski, Z., Nowakowska-Toporowska, A., Weżgowiec, J., & Nowakowska, D. (2019). Design and characteristics of new experimental chlorhexidine dental gels with anti-staining properties. Advances in Clinical and Experimental Medicine, 28(7), 885–890. https://doi.org/10.17211/acem/S4152

*Requena-Calla, S., & Funes-Rumiche, I. (2016). Effectiveness of intra-alveolar chlorhexidine gel in reducing dry socket following surgical extraction of lower third molars. A pilot study. Journal of Clinical and Experimental Dentistry, 8(2), e160–e163. https://doi.org/10.4317/jced.52444

Rodriguez Sanchez, F., Rodriguez Andres, C., & Arteagoitia Calvo, I. (2017). Does chlorhexidine prevent alveolar osteitis after third molar extractions? Systematic review and meta-analysis. Journal of Oral and Maxillofacial Surgery, 75(5), 901–914. https://doi.org/10.1016/j.joms.2017.01.002

*Rubio-Palau, J., Garcia-Linares, J., Hueto-Madrid, J. A., Gonzalez-Lagunas, J., Raspall-Martín, G., & Mareque-Bueno, J. (2015). Effect of intra-alveolar placement of 0.2% chlorhexidine bioadhesive gel on the incidence of alveolar osteitis following the extraction of mandibular third molars. A double-blind randomized clinical trial. Medicina Oral Patologia Oral y Cirugia Bucal, 20(11), e117–e122. https://doi.org/10.4317/medoral.20009

*Shaban, B., Azimi, H. R., Naderi, H., Janani, A., Zarrabi, M. J., & Nejat, A. (2014). Effect of 0.2% chlorhexidine gel on frequency of dry socket following mandibular third molar surgery: A double-blind clinical trial. Journal of Dental Materials and Techniques, 34), 175–179. https://doi.org/10.22038/jdmt.2014.3348

Sigron, G. R., Pourmand, P. P., Mache, B., Studinger, B., & Locher, M. C. (2014). The most common complications after wisdom-tooth removal: Part 1: A retrospective study of 1,199 cases in the mandible. Swiss Dental Journal, 124(10), 1052–1056.

Teshome, A. (2017). The efficacy of chlorhexidine gel in the prevention of alveolar osteitis after mandibular third molar extraction: A systematic review and meta-analysis. BMC Oral Health, 17(1), Article 82. https://doi.org/10.1186/s12903-017-0376-3

Tilliss, T. S. (1999). Use of a whitening dentifrice for control of chlorhexidine stain. The Journal of Contemporary Dental Practice, 1(1), 9–15.

Torres-Lagares, D., Gutierrez-Perez, J. L., Hita-Iglesias, P., Magallanes-Abad, N., Flores-Ruiz, R., Basallote-Garcia, M., & Gonzalez-Martín, M. (2010). Randomized, double-blind study of effectiveness of intra-alveolar application of chlorhexidine gel in reducing incidence of alveolar osteitis and bleeding complications in mandibular third molar surgery in patients with bleeding disorders. Journal of Oral and Maxillofacial Surgery, 68(6), 1322–1326. https://doi.org/10.1016/j.joms.2009.08.022

Torres-Lagares, D., Gutierrez-Perez, J. L., Infante-Cossio, P., Garcia-Calderon, M., Romero-Ruiz, M. M., & Serrera-Figallo, M. A. (2006). Randomized, double-blind study on effectiveness of intra-alveolar chlorhexidine gel in reducing incidence of alveolar osteitis in mandibular third molar surgery. International Journal of Oral and Maxillofacial Surgery, 35(4), 348–351. https://doi.org/10.1016/j.ijom.2005.08.002

Torres-Lagares, D., Infante-Cossio, P., Gutierrez-Perez, J. L., Romero-Ruiz, M. M., Garcia-Calderon, M., & Serrera-Figallo, M. A. (2006). Intra-alveolar chlorhexidine gel for the prevention of dry socket in mandibular third molar surgery. A pilot study. Medicina Oral, Patología Oral y Cirugía Bucal, 11(2), E179–E184.

Yenigopal, V., & Mickenauschtsch, S. (2012). Chlorhexidine for the prevention of alveolar osteitis. International Journal of Oral and Maxillofacial Surgery, 41(10), 1253–1264. https://doi.org/10.1016/j.ijom.2012.04.017

Younus, S., Ghumman, N. U., Latif, K., & Chishty, M. S. (2014). Efficacy of chlorhexidine gel vs chlorhexidine rinses in reducing incidence of dry socket in mandibular third molar surgery. Oral Diseases, 20(3), 249–252.